2.15Open2.15Pre Close0 Volume2 Open Interest6.00Strike Price0.00Turnover355.71%IV7.67%PremiumDec 20, 2024Expiry Date1.83Intrinsic Value100Multiplier7DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type-0.6884Delta0.1724Gamma1.94Leverage Ratio-0.0523Theta-0.0009Rho-1.33Eff Leverage0.0020Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet